Loss of heterozygosity at 3p24-p25 as a prognostic factor in breast cancer

Cancer Letters

Volumn 152, Issue 1, 2000, Pages 63-69

  Matsumoto, Satoshi ^a   Minobe, Kaori ^a   Utada, Yoshihito ^a,b   Furukawa, Kiyonori ^a   Onda, Masahiko ^a   Sakamoto, Goi ^b   Kasumi, Fujio ^b   Nakamura, Yusuke ^c   Emi, Mitsuru ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b CANCER INSTITUTE   (Japan)

^c THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

Breast cancer; Chromosome 3p; Loss of heterozygosity; Postoperative mortality; Tumor suppressor gene

Indexed keywords

DNA MARKER; MICROSATELLITE DNA;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CHROMOSOME 3P; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; PROGNOSIS; TIME FACTORS;

EID: 0034724963     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00431-0     Document Type: Article

References (37)

1. Callahan R., Campbell X. Mutations in human breast cancer: an overview. J. Natl. Cancer Inst. 81:1989;1780-1786.
2. Knudson A.G. Anti-oncogenes and human cancer. Proc. Natl. Acad. Sci. USA. 90:1993;10914-10921.
3. Ali I.U., Lidereau R., Callahan R. Presence of two members of c-erbA receptor gene family (c-erbA beta and c-erbA2) in smallest region of somatic homozygosity on chromosome 3p21-p25 in human breast carcinoma. J. Natl. Cancer Inst. 81:1989;1815-1820.
4. Bergthorsson J.T., Eiriksdottir G., Barkardottir R.B., Egilsson V., Arason A., Ingvarsson S. Linkage analysis and allelic imbalance in human breast cancer kindreds using microsatellite markers from the short arm of chromosome 3. Hum. Genet. 96:1995;437-443.
5. Buchhagen D.L., Qiu L., Etkind P. Homozygous deletion, rearrangement and hypermethylation implicate chromosome region 3p14.3-3p21.3 in sporadic breast-cancer development. Int. J. Cancer. 57:1994;473-479.
6. Chen L.C., Matsumura K., Deng G., Kurisu W., Ljung B.M., Lerman M.I., Waldman F.M., Smith H.S. Deletion of two separate regions on chromosome 3p in breast cancers. Cancer Res. 54:1994;3021-3024.
7. Eiriksdottir G., Bergthorsson J.T., Sigurdsson H., Gudmundsson J., Skirnisdottir S., Egilsson V., Barkardottir R.B., Incvarsson S. Mapping of chromosome 3 alterations in human breast cancer using microsatellite PCR markers: correlation with clinical variables. Int. J. Oncol. 6:1995;369-375.
8. Negrini M., Monaco C., Vorechovsky I., Ohta M., Druck T., Baffa R., Huebner K., Croce C.M. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res. 56:1996;3173-3179.
9. Pandis N., Jin Y., Limon J., Bardi G., Idvall I., Mandahl N., Mitelman F., Heim S. Interstitial deletion of the short arm of chromosome 3 as a primary chromosome abnormality in carcinomas of the breast. Genes Chromosomes Cancer. 6:1993;151-155.
10. Sato T., Tanigami A., Yamakawa K., Akiyama F., Kasumi F., Sakamoto G., Nakamura Y. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res. 50:1990;7184-7189.
11. Sato T., Akiyama F., Sakamoto G., Kasumi F., Nakamura Y. Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res. 51:1991;5794-5799.
12. Matsumoto S., Kasumi F., Sakamoto G., Onda M., Nakamura Y., Emi M. Detailed deletion mapping of chromosome arm 3p in breast cancers: a 2-cM region on 3p14.3-21.1 and a 5-cM region on 3p24.3-25.1 commonly deleted in tumors. Genes Chromosomes Cancer. 20:1997;268-274.
13. Harris J.R., Henderson I.C. Staging and prognostic factors. Harris J.R. Breast Diseases. 1987;327-346.
14. McGuire W., Clark G. Prognostic factors and treatment decision in axillary node-negative breast cancer. N. Engl. J. Med. 326:1992;1756-1761.
15. Japanese Breast Cancer Society, The general rules for clinical and pathological recording of breast cancer, Jpn. J. Surg. 19 (1989) 612-632.
16. Iida A., Yoshimoto M., Kasumi F., Nakamura Y., Emi M. Localization of breast cancer tumor-suppressor gene to a 3-cM interval within chromosomal region 16q22. Br. J. Cancer. 75:1997;264-267.
17. Hibi K., Takahashi T., Yamakawa K., Ueda R., Sekido Y., Ariyoshi Y., Suyama M., Takagi H., Nakamura Y., Takahashi T. Three distinct regions involved in 3p deletion in human lung cancer. Oncogene. 7:1992;445-449.
18. van den Berg A., Hulsbeek M.M.F., de Jong D., Kok K., Veldhuis P.M.J.F., Roche J., Buys C.H.C.M. Major role for a 3p21 region and lack of involvement of the t (3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis. Genes Chromosomes Cancer. 15:1996;64-72.
19. Wu C.L., Sloan P., Read A.P., Harris R., Thakker N. Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Res. 54:1994;6484-6488.
20. Roz L., Wu C.L., Porter S., Scully C., Speight P., Read A., Sloan P., Thakker N. Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Cancer Res. 56:1996;1228-1231.
21. Rimessi P., Gualandi F., Morelli C., Trabanelli Q., Wu L., Possati M., Montesi J.C., Barrett B.C., Barbanti-Brodano G. Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. Oncogene. 9:1994;3467-3474.
22. Chen L.C., Kurisu W., Ljung B.M., Goldman E.S., Moore II D., Smith H.S. Heterogeneity for allelic loss in human breast cancer. J. Natl. Cancer Inst. 84:1992;506-510.
23. Man S., Ellis I.O., Sibbering M., Blamey R.W., Brook J.D. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and tubular invasive breast cancers. Cancer Res. 56:1996;5409-5484.
24. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T., Croce C.M., Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 84:1996;587-597.
25. Sozzi G., Veronese M.L., Negrini M., Baffa R., Cotticelli M.G., Inoue H., Tornielli S., Pilotti S., de Gregorio L., Pastorio U., Pierotti M.A., Ohta M., Huebner K., Croce C.M. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell. 85:1996;17-26.
26. Negrini M., Monaco C., Vorechovsky I., Ohta M., Druck T., Baffa R., Huebner K., Croce C.M. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res. 56:1996;3173-3179.
27. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.M. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
28. Varley J.M., Swallow J.E., Brammar W.J., Whittaker J.L., Walker R.A. Alterations to either c-erbB2 or c-myc proto-oncogenes in breast carcinoma correlate with poor short-term prognosis. Oncogene. 1:1987;423-430.
29. Borg A., Tandon A.K., Sigurdsson H., Clark G.M., Fearon M., Fuqua S.A.W., et al. HER-2/new amplification predicts poor survival in node-positive breast cancer. Cancer Res. 50:1990;4332-4337.
30. Borg A., Baldetorp B., Ferno M., Killander D., Olsson H., Igurdsson H. amplification in breast cancer with a high rate of proliferation. Oncogene. 6:1991;137-14334.
31. Berns E.M., Klijn J.G.M., Van Staveren I.L., Portengen H., Noordegraaf E., Foekens J.A. Prevalence of amplification of the oncogenes c-myc HER-2/neu, and int-2 in one thousand human breast tumors: correlation with steroid receptors. Eur. J. Cancer. 213:1992;697-700.
32. Tompson A.M., Steel C.M., Chetty U., Hawkins R.A., Miller W.R., Carter D.C., et al. gene mRNA expression and chromosome 17p allele loss in breast cancer. Br. J. Cancer. 61:1990;74-78.
33. Elledge R.M., Fuqua S.A.W., Clark G.M., Allred D.C., McGuire W.L. Prognostic significance of p53 gene mutations in node-negative breast cancer. Breast Cancer Res. Treat. 26:(1):1993;225-235.
34. Deng G., Chen L.C., Schott D.R., Thor A., Bhargava V., Ljung B.M., et al. of heterozygosity and p53 gene mutations in breast cancer. Cancer Res. 54:1994;499-505.
35. Bieche I., Champeme M.H., Matifas F., Hacene K., Callahan R., Lidereau R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet. 339:1992;139-143.
36. Catzavelos C., Bhattacharya N., Ung Y., Wilson J.A., Roncari L., Sandhu C., et al. Decreased levels of the cell-cycle inhibitor p27-Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 3:1997;227-230.
37. Porter P., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J., et al. of cell-cycle regulators p27-kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:1997;222-225.